Acute treatment with monoclonal antibodies: their design and their use
Passive anti-viral immunotherapy, including monoclonal antibodies (mAb), was identified early as a promising therapeutic avenue for COVID-19 with a rapid development pathway. This has been driven by the lack of existing effective direct acting antivirals for coronaviruses, the marginal clinical impa...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
CSIRO Publishing
2021-01-01
|
| Series: | Microbiology Australia |
| Online Access: | https://www.publish.csiro.au/ma/pdf/MA21011 |